PD-protec® is a novel fluid for peritoneal dialysis (PD). The product is being developed to significantly improve and prolong the survival of patients undergoing PD.

A randomized, double-blinded, multicenter Phase II trial was completed in late 2016. The two primary endpoints of the trial were successfully met.

Both endpoints were chosen to reflect clinically highly relevant aspects of PD treatment:

 ● a reduced risk of peritoneal membrane failure and
 ● a lower risk of peritonitis.

PD-protec® appeared to be well tolerated with no serious adverse events and exhibited a comparable safety profile to the current standard-of-care fluid. No adverse events were observed, corroborating the safety profile seen in earlier trials.

The active substance in PD-protec® is alanyl-glutamine, a dipeptide with a pharmacological and tolerability profile that is well-proven in parenteral (intravenous) nutrition.

PD-protec® is patent protected.